CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Faculty Medicine Year: 2019
Type of Publication: ZU Hosted Pages:
Authors:
Amarallah Abdelmoneim Mohamed Sayed
Journal: Oncology Reviews PAGEPress, Italy Volume:
Keywords : CDK4/6 inhibitors , advanced breast cancer, what    
Abstract:
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.
    
     
 
       

Author Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Myelodysplastic syndrome from theoretical review to clinical application view", PAGEPress, Italy, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Patterns of Inpatient Admissions during Haj Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia", Pak J Med Sci, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer", Symbiosis, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience", Remedy Publications LLC, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "?Aggressive Care at the End of Life; Where Are We", Wolters Kluwer - Medknow, 2019 More

Department Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "The Relation Between the Timing of Palliative Care and the Frequency and Timing of Do-Not-Resuscitate Orders Among Cancer Deaths in a Tertiary Care Hospital", ajhpm.sagepub.com, 2015 More
  • Amarallah Abdelmoneim Mohamed Sayed, "For pathological response to neoadjuvant chemotherapy in hormonal receptors-positive breast cancer", Asian Pacific Journal of Cancer Prevention, 2015 More
  • Heba Fekry Abdel Majid Taha, "The Value of FAK and SLUG Expression in Patients with Breast Carcinoma and Relation of Their Expression to Clinicopathological and Prognostic Parameters", Copyright © 2018, SciTechnol, 2018 More
Tweet